DSpace About DSpace Software 日本語

01 奈良県立医科大学 >
012 大学院 >
0122 学位請求論文 >
01221 博士論文(医学) >
2021年度 >

Please use this identifier to cite or link to this item: http://hdl.handle.net/10564/4020

Title: Efficacy of combination of transarterial chemoembolization and radiation therapy for patients with hepatocellular carcinoma ineligible for resection or radiofrequency ablation.
Other Titles: 切除およびラジオ波凝固療法が適応外と判断された肝細胞癌症例に対する経動脈的化学塞栓療法と放射線療法の併用療法の効果
Authors: Inoue, Masayoshi
Takahama, Junko
Kunichika, Hideki
Shimoda, Emiko
Morimoto, Kengo
Nikimoto, Mei
Inooka, Nobuyoshi
Hasegawa, Masatoshi
Keywords: hepatocellular carcinoma
radiation therapy
stereotactic body radiotherapy
trans-arterial chemoembolization
radiofrequency ablation
treatment outcome
Issue Date: 2022
Publisher: 奈良医学会
Citation: Journal of Nara Medical Association Vol.73 No.1,2,3 p.01-09 (2022.06)
Abstract: Purpose: The local control rate of trans-arterial chemoembolization (TACE) for the patients with hepatocellular carcinoma (HCC) was unsatisfactory compared to resection or radiofrequency ablation (RFA). We performed radiation therapy after TACE to increase the control rate in our institution. The purpose of this study was to evaluate the efficacy and toxicity of the TACE and radiotherapy combination in HCC patients ineligible for resection or RFA. Material and Methods: Between January 2017 and April 2020, 33 patients with HCC ineligible for resection or RFA were treated with a combination of TACE and radiation therapy. Eight patients were initial cases, and 25 were recurrent or residual cases. A total dose of 40-60 Gy in 5-20 fractions was delivered to the 50-90% isodose line. Results: The median follow-up period was 16 months (range, 6-47 months); objective response rate, 66.7%; and the 1- and 2-year overall survival rates, 72.7% and 62.5%, respectively. The objective response rate of HCCs <5 cm was 79.2%; the 1- and 2-year overall survival rates, 91.7% and 62.5%, respectively; median progression-free survival, 13.5 months (range, 3-47 months), and the 1- and 2-year local progression-free survival rates, 95.8% and 85.7%, respectively. There was one case each of grade 2 radiation esophagitis and ascites after three months of irradiation. Conclusion: The combination of TACE and radiation therapy shows good local control and acceptable toxicity, particularly in HCCs <5 cm and may be a good treatment option.
Description: 博士(医学)・甲第837号・令和4年3月15日
URI: http://hdl.handle.net/10564/4020
ISSN: 13450069
Academic Degrees and number: 24601A837
Degree-granting date: 2022-03-15
Degree name: 博士(医学)
Degree-granting institutions: 奈良県立医科大学
Appears in Collections:2021年度

Files in This Item:

File Description SizeFormat
01甲837本文の要旨.pdf甲837本文の要旨1.82 MBAdobe PDFView/Open
02甲837審査要旨.pdf甲837審査要旨219.38 kBAdobe PDFView/Open
03甲837本文.pdf甲837本文807.82 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.


Valid XHTML 1.0! DSpace Software Copyright © 2002-2010  Duraspace - Feedback